Abridge
Worth-Joining Index · Scorecard
v2.1 ALPHA · 2026-08Career Score
—/100
Coverage
60%
Verified
0%
Stage cohort
Growth
Vibe Check
🎪 community voting coming soon
Latest valuation
$5.3B (Series E, 2025-06)
Traction · Key numbers
Funding
Rounds
3
Valuation pace
$2.75B
$316M
Series E extension · 2026-04 · valuation $5.3B post (Series E, 2025-06) · led by Andreessen Horowitz (a16z)
With: Khosla Ventures, NVentures, Lightspeed, Bessemer Venture Partners · Valuation held flat at $5.3B
$300M
Series E · 2025-06 · valuation $5.3B post · led by Andreessen Horowitz
With: Khosla Ventures
$250M
Series D · 2025-02 · valuation $2.75B post
▸Valuation curve is the story: $2.75B to $5.3B in four months, but the Apr 2026 extension held flat at $5.3B — a signal that growth expectations are meeting resistance
▸a16z led both the Series E and the extension — high conviction, but also means no fresh price discovery from new investors since June 2025
▸By multiple, Abridge is the highest-valued pure-play in AI medical scribing — if growth disappoints, this is where the correction risk concentrates
Founders
Shiv Rao CEO
Cardiologist by training; founded Abridge in 2018 after practicing medicine at UPMC
Sandeep Konam Co-Founder/CTO
Co-founder, technical/CTO lead
Florian Metze Co-Founder/CSO
Co-founder, speech and machine learning background
Reality · Working here
Signals & Risks
Editorial ✎
Good fit for
· Engineers who want AI applied to healthcare and are willing to grind through EHR integration — the moat here is Epic-depth integration, not the model itself
· PMs with clinical empathy or healthcare background — physician trust is the core moat, and you can't build for doctors without understanding their workflow
· People comfortable working under scrutiny in a highly-valued, closely-watched category — Abridge carries the highest valuation among pure-play AI scribes
Not for
· Those who want move-fast, unregulated iteration speed — healthcare's compliance, privacy, and approval cycles are inherently slower
· Those unprepared for big-tech competition — Microsoft/Nuance DAX has the Office/Teams distribution advantage, and rivals like Ambience are equally well-funded
Ask in the interview
1. Why did valuation stay flat at the April 2026 extension — slowing growth, or a deliberate conservative pricing choice?
2. Is the relationship with Epic and other EHR platforms revenue-share or pure technical integration? What happens to Abridge's position if Epic builds native scribe features?
3. Beyond clinical accuracy and specialty coverage, what's the moat that's genuinely hard for Ambience or Microsoft DAX to replicate?
Data changelog
Community corrections → editorial review → applied, fully on the record
Want to talk about this company?
Community members may work here or have interviewed — corrections and additions welcome too
Join the discussion